Provided by Tiger Fintech (Singapore) Pte. Ltd.

TBG Diagnostics

0.270
0.000
Volume:- -
Turnover:- -
Market Cap:58.75M
PE:-16.55
High:0.270
Open:0.270
Low:0.270
Close:0.270
52wk High:0.270
52wk Low:0.270
Shares:217.59M
Float Shares:47.95M
Volume Ratio:4.16
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.016
EPS(LYR):-0.016
ROE:-38.05%
ROA:-14.30%
PB:10.13
PE(LYR):-16.55

Loading ...

Company Profile

Company Name:
TBG Diagnostics
Exchange:
ASX
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
TBG Diagnostics Limited, a molecular diagnostics company, researches, develops, manufactures, and markets molecular diagnostics kits, assays, instruments, and services in the United States, Taiwan, and China. The company offers nucleic acid extraction, human leukocyte antigen (HLA) sequence specific primer typing, HLA sequence based typing, and HPA genotyping kits, as well as reagents and accessories, holotype HLA NGS products, and reagents analysis software; equipment comprising nucleic acid extraction, automated pipetting, and gel electrophoresis systems; and HLA genotyping and manufacturing services. It serves clinical labs of hospitals and independent reference labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 and is based in Greenslopes, Australia.